A bunch of Canadian news outlets are in a tizzy, suing OpenAI for allegedly using their content without permission. The Read more
India-based audio platform Pocket FM has a vast content library. However, CEO Rohan Nayak believes there is room for expansion Read more
ChatGPT Search, OpenAI's AI-powered web search experience, has officially launched for all ChatGPT users, introducing several new features to enhance Read more
Humanz, a cutting-edge marketing platform for content creators and brands, has officially made its debut in the U.S. market, as Read more
Pharmaceutical company Regeneron has announced its plans to acquire genetic testing company 23andMe for $256 million following a bankruptcy auction. This deal includes 23andMe’s genomics service and its database of 15 million customers’ personal and genetic data. Regeneron aims to utilize this customer data for drug discovery purposes, emphasizing its commitment to prioritizing privacy, security, and ethical use of the information.
23andMe filed for bankruptcy protection in March after a data breach exposed the private and genetic data of 7 million customers in 2023. The company’s stock price also drastically declined due to diminishing consumer interest in its DNA testing kits, leading to the resignation of founder and CEO Anne Wojcicki.
Following the bankruptcy filing, a federal bankruptcy court was tasked with overseeing the sale of 23andMe’s assets, raising concerns about the potential sale of customer data to hostile entities or unethical buyers. Regeneron, as the winning bidder in the auction, has stated its commitment to ensuring compliance with 23andMe’s privacy policies and relevant laws governing customer data.
The bankruptcy court is scheduled to review Regeneron’s acquisition on June 17, with the company clarifying that it will not be acquiring 23andMe’s Lemonaid Health business.
